Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib—a biological or synthetic target specific) in patients hospitalized with COVID-19

Abstract

The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field to standardize how to conduct and to assist in the reasoning and decision-making of doctors. The information provided by this project must be critically evaluated by the physician responsible for the conduct that will be adopted, depending on the conditions and the clinical condition of each patient. Guideline conclusion: November 2021.